First-line immunotherapy for non–small-cell lung cancer
For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has
been characterized by critical progress that has contributed to substantially improved …
been characterized by critical progress that has contributed to substantially improved …
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
G Morad, BA Helmink, P Sharma, JA Wargo - Cell, 2021 - cell.com
Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
L Kraehenbuehl, CH Weng, S Eghbali… - Nature reviews Clinical …, 2022 - nature.com
The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the …
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the …
Therapeutic targeting of the tumor microenvironment
L Bejarano, MJC Jordāo, JA Joyce - Cancer discovery, 2021 - AACR
Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a
promising approach for cancer treatment in recent years due to the critical roles of the TME …
promising approach for cancer treatment in recent years due to the critical roles of the TME …
[HTML][HTML] Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses
KL Banta, X Xu, AS Chitre, A Au-Yeung, C Takahashi… - Immunity, 2022 - cell.com
Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early
results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT …
results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT …
Immunotherapy: reshape the tumor immune microenvironment
B Lv, Y Wang, D Ma, W Cheng, J Liu, T Yong… - Frontiers in …, 2022 - frontiersin.org
Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc.
The interactions between these components, which are divided into anti-tumor and pro …
The interactions between these components, which are divided into anti-tumor and pro …
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
L Cai, Y Li, J Tan, L Xu, Y Li - Journal of hematology & oncology, 2023 - Springer
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …
[HTML][HTML] Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients
with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly …
with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly …
[HTML][HTML] TIGIT in cancer immunotherapy
JM Chauvin, HM Zarour - Journal for immunotherapy of cancer, 2020 - ncbi.nlm.nih.gov
Tumors evade immune-mediated recognition through multiple mechanisms of immune
escape. On chronic tumor antigen exposure, T cells become dysfunctional/exhausted and …
escape. On chronic tumor antigen exposure, T cells become dysfunctional/exhausted and …
Immune checkpoint signaling and cancer immunotherapy
Immune checkpoint blockade therapy has become a major weapon in fighting cancer.
Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such …
Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such …